Skip to content

Xenogenic Keratoplasty From Porcine Cornea

Phase I Study of Xenogenic Keratoplasty From Porcine Cornea in the Treatment of Infectious Corneal Ulcer

Status
Suspended
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01443559
Acronym
XKFPC
Enrollment
20
Registered
2011-09-29
Start date
2011-09-30
Completion date
2015-12-31
Last updated
2015-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Porcine Corneal Xenograph

Keywords

Xenogenic

Brief summary

Acellular porcine cornea is a valid substitution for human cornea because of its similar biological structure, corneal superficial curvature and good histocompatibility toward human. Facing the lack of human cornea donor, it is hypothesised that using acellular lamellar porcine cornea as an alternative of lamellar human cornea to treat infectious corneal ulcer.

Detailed description

Acellular porcine cornea eligibility criteria: 1. fresh porcine cornea, 2. porcine cornea keeping transparent without scar, neovascularization or corneal ulcer, 3. porcine cornea keeping integrative corneal epithelium and endothelium, 4. acellular porcine cornea keeping transparent.

Interventions

GENETICXenogenic cornea

lamellar acellular xenogenic corneas were sterilised by radiation

GENETIChomogenic cornea

homogenic corneas were sterilised by radiation

Sponsors

Xiamen University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patients with severe infectious corneal ulcer * The ulcers can not be controlled with existing antibiotics eye drops or medicine after 1 week treatment * The infected corneas have risks of penetrating * The depth of ulcers are less than 400um * The bridge of the ulcers is away from corneal limbal more than 1mm * Patients aged 18 or older * Patients able and willing to sign the informed consent form

Exclusion criteria

* Patients with severe infectious corneal ulcer in stable stage * Patients with corneal ulcers after viruses infection, such as herpes simplex virus * Patients with corneal ulcers from non-infectious factors, such as toxicity, burn or immunological inflammation * The ulcers are not cover pupil zone and will not result in visional defect in future * The depth of ulcer is less than 50um * Patients has history of keratoplasty surgery

Design outcomes

Primary

MeasureTime frameDescription
Rate of rejection in three months after keratoplastythree months after lamellar keratoplasty1. Rate of epithelium rejection Epithelial rejection performances: 1.1 epithelium edema, OR 1.2 epithelium opacity, OR 1.3 epithelial rejection line. 2. Rate of stroma rejection Stroma rejection performances: 2.1 stroma edema, OR 2.2 stroma opacity, OR 2.3 suture loosing.

Secondary

MeasureTime frameDescription
Density of regenerative sub-epithelial nerve plex, stromal nerve and stromal keratocytes in vivo confocal microscopyone yearShapes and location: 1. Sub-epithelial nerve plex is in the depth between 35um to 65um shaping like white thin line with branches in vivo confocal microscopy. 2. Sromal nerve is in the stromal layer(about 70um to 500um) shaping like white thick trunk with branches in vivo confocal microscopy. 3. Stromal keratocytes is in the stromal layer like white rod-shape in vivo confocal microscopy.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026